lomustine has been researched along with Local Neoplasm Recurrence in 175 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma." | 9.69 | Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 9.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide." | 9.22 | Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. ( Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V, 2016) |
| "In this side study of the BELOB trial, 141 patients with recurrent glioblastoma were randomised to receive single-agent bevacizumab or lomustine, or bevacizumab plus lomustine." | 9.20 | Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. ( Beerepoot, L; Beije, N; de Vos, FY; Gratama, JW; Hanse, M; Kraan, J; Oosterkamp, HM; Otten, A; Sleijfer, S; Taal, W; van den Bent, MJ; van der Holt, B; van Linde, ME; Vernhout, RM; Walenkamp, AM, 2015) |
| " Adult patients (≥18 years of age) with a first recurrence of a glioblastoma after temozolomide chemoradiotherapy were randomly allocated by a web-based program to treatment with oral lomustine 110 mg/m(2) once every 6 weeks, intravenous bevacizumab 10 mg/kg once every 2 weeks, or combination treatment with lomustine 110 mg/m(2) every 6 weeks and bevacizumab 10 mg/kg every 2 weeks." | 9.19 | Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. ( Beerepoot, LV; Boerman, D; Brandsma, D; Bromberg, JE; Buter, J; de Vos, FY; Dinjens, WN; Dubbink, HJ; Enting, RH; Hanse, MC; Honkoop, AH; Jansen, RL; Oosterkamp, HM; Taal, W; Taphoorn, MJ; van den Bent, MJ; van den Berkmortel, FW; van der Holt, B; van Heuvel, I; Vernhout, RM; Walenkamp, AM, 2014) |
| "This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma, although cediranib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects." | 9.17 | Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. ( Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J, 2013) |
| "This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4)." | 9.14 | Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. ( Carpentier, AF; Chamberlain, MC; Cher, LM; Fine, HA; Hong, S; Liepa, AM; Mason, W; Musib, L; Puduvalli, VK; Thornton, DE; van den Bent, MJ; Weller, M; Wick, W, 2010) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 9.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "A prospective controlled randomized trial testing adjuvant postoperative combination chemotherapy (5-fluorouracil, lomustine (CCNU) and vincristine) versus no adjuvant therapy in patients operated on for Dukes' C colorectal cancer is reported." | 9.06 | Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. ( Asklöf, G; Bergman, L; Domellöf, L; Hafström, L; Hansson, K; Kugelberg, C; Nilsson, T; Norryd, C; Rudenstam, CM; Wählby, L, 1990) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| " Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone." | 8.31 | T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023) |
| "A first-line therapeutic for high-grade glioma, notably glioblastoma (GBM), is the DNA methylating drug temozolomide (TMZ)." | 8.12 | Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. ( Beltzig, L; Christmann, M; Kaina, B, 2022) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 8.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "The aim of this study was to assess the efficacy and tolerability of lomustine, methotrexate and cytarabine chemotherapy as rescue treatment for feline lymphoma." | 8.02 | Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma. ( Blackwood, L; Harper, A; Smallwood, K, 2021) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 7.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| "BD regimen combined with cyclophosphamide and pirarubicin chemotherapy can improve the response rate of patients with relapse/refractory multiple myeloma, and shows the trend of prolonging PFS and survival times." | 7.83 | [Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma]. ( Chen, YL; Ma, XH; Qiu, ZY; Ren, CA; Wang, YF; Xu, WJ, 2016) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 7.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 7.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)." | 7.70 | Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999) |
| "To determine the efficacy of the combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas after failure of either previous radiotherapy alone or previous radiotherapy plus nitrosourea-based chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 7.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 7.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV)." | 7.66 | Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. ( Crafts, DC; Edwards, MS; Levin, VA; Pischer, TL; Wilson, CB, 1978) |
| "Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors." | 6.87 | Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. ( Andre, C; Bouttens, F; Chaskis, C; D'Haene, N; Du Four, S; Duerinck, J; Le Mercier, M; Michotte, A; Neyns, B; Rogiers, A; Salmon, I; Van Fraeyenhove, F; Verschaeve, V, 2018) |
| " The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily)." | 6.77 | EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. ( Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C, 2012) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 6.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Glioblastomas are the most common malignant primary intrinsic brain tumors." | 6.66 | How did lomustine become standard of care in recurrent glioblastoma? ( Le Rhun, E; Weller, M, 2020) |
| " Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma." | 5.69 | Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023) |
| " To improve treatment, voriconazole dosage was adapted to reach drug concentrations in cerebrospinal fluid (CSF) above the minimal fungicidal concentration and plasma specimens." | 5.34 | Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. ( Burhenne, J; Foell, JL; Reiss, T; Rengelshausen, J; Staege, MS; Stiefel, M; Wawer, A, 2007) |
| " All patients required dosage modification for toxicity." | 5.28 | Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. ( Evans, AE; Lefkowitz, IB; Packer, RJ; Schut, L; Siegel, KR; Sutton, LN, 1990) |
| "We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide." | 5.22 | Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. ( Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V, 2016) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 5.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "The BELOB study, a randomised controlled phase 2 trial comparing lomustine, bevacizumab and combined lomustine and bevacizumab in patients with recurrent glioblastoma, showed that the 9-month overall survival rate was most promising in the combination arm." | 5.20 | The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. ( Beerepoot, LV; Bottomley, A; Bromberg, JE; de Vos, FY; Dirven, L; Hanse, MC; Otten, A; Reijneveld, JC; Smits, M; Taal, W; Taphoorn, MJ; van den Bent, MJ; van der Holt, B; van der Meer, N; Vos, MJ; Walenkamp, AM, 2015) |
| "In this side study of the BELOB trial, 141 patients with recurrent glioblastoma were randomised to receive single-agent bevacizumab or lomustine, or bevacizumab plus lomustine." | 5.20 | Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. ( Beerepoot, L; Beije, N; de Vos, FY; Gratama, JW; Hanse, M; Kraan, J; Oosterkamp, HM; Otten, A; Sleijfer, S; Taal, W; van den Bent, MJ; van der Holt, B; van Linde, ME; Vernhout, RM; Walenkamp, AM, 2015) |
| " Adult patients (≥18 years of age) with a first recurrence of a glioblastoma after temozolomide chemoradiotherapy were randomly allocated by a web-based program to treatment with oral lomustine 110 mg/m(2) once every 6 weeks, intravenous bevacizumab 10 mg/kg once every 2 weeks, or combination treatment with lomustine 110 mg/m(2) every 6 weeks and bevacizumab 10 mg/kg every 2 weeks." | 5.19 | Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. ( Beerepoot, LV; Boerman, D; Brandsma, D; Bromberg, JE; Buter, J; de Vos, FY; Dinjens, WN; Dubbink, HJ; Enting, RH; Hanse, MC; Honkoop, AH; Jansen, RL; Oosterkamp, HM; Taal, W; Taphoorn, MJ; van den Bent, MJ; van den Berkmortel, FW; van der Holt, B; van Heuvel, I; Vernhout, RM; Walenkamp, AM, 2014) |
| "This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma, although cediranib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects." | 5.17 | Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. ( Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J, 2013) |
| "This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4)." | 5.14 | Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. ( Carpentier, AF; Chamberlain, MC; Cher, LM; Fine, HA; Hong, S; Liepa, AM; Mason, W; Musib, L; Puduvalli, VK; Thornton, DE; van den Bent, MJ; Weller, M; Wick, W, 2010) |
| "When administered according to a monthly schedule, carboplatin exhibited modest activity in adult patients with recurrent or progressive oligodendroglioma or oligoastrocytoma who experienced treatment failure after PCV chemotherapy; the current treatment regimen also was associated with severe toxicity." | 5.11 | Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. ( Borgognone, M; Costanza, A; Laguzzi, E; Mutani, R; Nobile, M; Rudà, R; Soffietti, R, 2004) |
| "The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas." | 5.10 | Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003) |
| "A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas." | 5.08 | Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997) |
| "A prospective controlled randomized trial testing adjuvant postoperative combination chemotherapy (5-fluorouracil, lomustine (CCNU) and vincristine) versus no adjuvant therapy in patients operated on for Dukes' C colorectal cancer is reported." | 5.06 | Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. ( Asklöf, G; Bergman, L; Domellöf, L; Hafström, L; Hansson, K; Kugelberg, C; Nilsson, T; Norryd, C; Rudenstam, CM; Wählby, L, 1990) |
| "A number of cooperative-group and single-institution studies have shown that BCNU used in combination with prednisone alone or with melphalan,cyclophosphamide, and prednisone is useful for remission induction in patients with previously untreated multiple myeloma." | 5.04 | Nitrosoureas in multiple myeloma. ( Salmon, SE, 1976) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| " Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone." | 4.31 | T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023) |
| "A first-line therapeutic for high-grade glioma, notably glioblastoma (GBM), is the DNA methylating drug temozolomide (TMZ)." | 4.12 | Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. ( Beltzig, L; Christmann, M; Kaina, B, 2022) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 4.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "The aim of this study was to assess the efficacy and tolerability of lomustine, methotrexate and cytarabine chemotherapy as rescue treatment for feline lymphoma." | 4.02 | Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma. ( Blackwood, L; Harper, A; Smallwood, K, 2021) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 3.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| "BD regimen combined with cyclophosphamide and pirarubicin chemotherapy can improve the response rate of patients with relapse/refractory multiple myeloma, and shows the trend of prolonging PFS and survival times." | 3.83 | [Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma]. ( Chen, YL; Ma, XH; Qiu, ZY; Ren, CA; Wang, YF; Xu, WJ, 2016) |
| "In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen." | 3.80 | Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014) |
| "Sixty-four patients who received at least one cycle of a nitrosourea agent (nimustine or lomustine) and teniposide for recurrent glioma between 2008 and 2012; of these patients, 28 did not receive prophylactic pegfilgrastim (cohort A), and 36 patients received prophylactic pegfilgrastim (cohort B)." | 3.80 | Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma. ( Atta, J; Franz, K; Lemercier, S; Rieger, J; Steinbach, JP; Sulzbacher, A; Thiepold, AL, 2014) |
| "To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data." | 3.73 | Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006) |
| "The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy." | 3.71 | PCV chemotherapy for recurrent glioblastoma multiforme. ( Groeneveld, GJ; Heimans, JJ; Kappelle, AC; Postma, TJ; Sneeuw, KC; Taphoorn, MJ; van den Bent, MJ; van Groeningen, CJ; Zonnenberg, BA, 2001) |
| "We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery." | 3.70 | Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999) |
| "The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)." | 3.70 | Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999) |
| "Nine patients with stage III and stage IV thymoma were treated with cisplatin, vincristine, lomustine, cyclophosphamide and prednisolone." | 3.69 | Combination chemotherapy with a five-drug regimen for invasive thymoma. ( Bjerrum, OW; Daugaard, G; Kiss, K, 1996) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 3.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "To determine the efficacy of the combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas after failure of either previous radiotherapy alone or previous radiotherapy plus nitrosourea-based chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 3.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV)." | 3.66 | Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. ( Crafts, DC; Edwards, MS; Levin, VA; Pischer, TL; Wilson, CB, 1978) |
| "Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors." | 2.87 | Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. ( Andre, C; Bouttens, F; Chaskis, C; D'Haene, N; Du Four, S; Duerinck, J; Le Mercier, M; Michotte, A; Neyns, B; Rogiers, A; Salmon, I; Van Fraeyenhove, F; Verschaeve, V, 2018) |
| " The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily)." | 2.77 | EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. ( Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C, 2012) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 2.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "The management of androgen independent prostate cancer is increasingly disputed." | 2.71 | Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. ( Ansell, W; Barlow, C; Dancey, G; Oliver, RT; Shamash, J; Wilson, P, 2005) |
| "Lomustine was only given for the first three cycles." | 2.67 | Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group. ( Allard, P; Boita, F; Chastang, C; Fichet, D; Lebeau, B; Migueres, J, 1992) |
| "Glioblastomas are the most common malignant primary intrinsic brain tumors." | 2.66 | How did lomustine become standard of care in recurrent glioblastoma? ( Le Rhun, E; Weller, M, 2020) |
| "Glioblastomas are rich in blood vessels (i." | 2.58 | Anti-angiogenic therapy for high-grade glioma. ( Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H, 2018) |
| "I." | 2.44 | Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. ( Cheng, S; Evans, WK; Shepherd, FA; Stys-Norman, D, 2007) |
| "Conservative procedures to treat rectal cancer are also gaining support because of reduced morbidity and mortality, avoidance of colostomy, and excellent survival figures in selected patients." | 2.38 | Surgical therapy of early rectal carcinoma. ( Curley, SA; Rich, TA; Roh, MS, 1989) |
| " Using immunocompetent orthotopic glioma mouse models, we identified strong anti-glioma activity of L19TNF in combination with the alkylating agent CCNU, which cured the majority of tumor-bearing mice, whereas monotherapies only had limited efficacy." | 1.91 | Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma. ( Amit, I; Becher, B; Bühler, M; De Luca, R; Di Nitto, C; Hemmerle, T; Katzenelenbogen, Y; Kirschenbaum, D; Look, T; Neri, D; Puca, E; Ravazza, D; Rindlisbacher, L; Roth, P; Stucchi, R; Weiner, A; Weiss, T; Weller, M, 2023) |
| "Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide." | 1.72 | Current therapeutic options for glioblastoma and future perspectives. ( Aquilanti, E; Wen, PY, 2022) |
| "Lomustine was administered, but 1 year after surgery, the dog exhibited cluster seizures and died." | 1.43 | Case of a miniature dachshund with a primitive neuroectodermal tumor confined to the forebrain region treated with a combination of surgery and chemotherapy. ( Matsunaga, S; Nakamoto, Y; Ozawa, T; Uchida, K; Yamada, A, 2016) |
| "Patients with desmoplastic medulloblastoma and lateral tumour location (n=19) had a lower EFS compared to patients with centrally located desmoplastic tumours (n=10) (p=0." | 1.39 | Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study. ( Deinlein, F; Friedrich, C; Hau, P; Kortmann, RD; Kuehl, J; Kwiecien, R; Pietsch, T; Rutkowski, S; von Bueren, AO; von Hoff, K; Warmuth-Metz, M, 2013) |
| "38 cats with measurable, histologically or cytologically confirmed MCTs treated with lomustine at a dosage > or = 50 mg/m(2)." | 1.35 | Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). ( Al-Sarraf, R; Baez, JL; Dank, G; Kristal, O; Rassnick, KM; Williams, LE; Zwahlen, CH, 2008) |
| " To improve treatment, voriconazole dosage was adapted to reach drug concentrations in cerebrospinal fluid (CSF) above the minimal fungicidal concentration and plasma specimens." | 1.34 | Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. ( Burhenne, J; Foell, JL; Reiss, T; Rengelshausen, J; Staege, MS; Stiefel, M; Wawer, A, 2007) |
| "Visual impairment was detected in 14 pts (24%), associated with recurrence (p = ." | 1.32 | Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap. ( Jereb, B; Macedoni-Luksic, M; Todorovski, L, 2003) |
| "Several protocols for the adjuvant treatment of glioblastoma multiforme (GBM) are currently being evaluated." | 1.31 | Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo. ( Deininger, MH; Grote, E; Meyermann, R; Wickboldt, J, 2000) |
| "Esthesioneuroblastomas are radiocurable tumors." | 1.31 | Radiotherapy of esthesioneuroblastoma. ( Eich, HT; Eich, PD; Micke, O; Müller, R; Staar, S; Stützer, H, 2001) |
| " All patients required dosage modification for toxicity." | 1.28 | Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. ( Evans, AE; Lefkowitz, IB; Packer, RJ; Schut, L; Siegel, KR; Sutton, LN, 1990) |
| "Although most patients with Hodgkin's disease refractory to MOPP treatment will respond to either ABVD or B-CAVe chemotherapy, subsequent long-term disease-free survival is unusual." | 1.27 | Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. ( Harker, WG; Kushlan, P; Rosenberg, SA, 1984) |
| "5 g/M2 every six weeks, with dosage adjustments for myelotoxicity." | 1.27 | Misonidazole and CCNU chemotherapy for recurrent primary brain tumor. ( Fulton, DS; McKinnon, S; Tanasichuk, H; Urtasun, RC, 1987) |
| "One patient with gastric cancer attained a partial remission with a duration of remission of 9." | 1.26 | [Clinical and therapeutic study (phase II) using VP-16/213 and methyl-CCNU in patients with inoperable, recurring or metastasizing carcinomas of the gastriointestinal tract]. ( Hartmann, D; Obrecht, JP; Stalder, GA, 1978) |
| "34 patients operated on for malignant gliomas were successively treated by combination chemotherapy with VM26 and CCNU and conventional radiation therapy with an average dosage of 5,800 Rads, six months after surgery." | 1.26 | Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy. ( Bataini, JP; Hauw, JJ; Mashaly, R; Metzger, J; Pertuiset, BF; Poisson, M; Pouillart, P, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (28.57) | 18.7374 |
| 1990's | 28 (16.00) | 18.2507 |
| 2000's | 34 (19.43) | 29.6817 |
| 2010's | 46 (26.29) | 24.3611 |
| 2020's | 17 (9.71) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamuro, S | 1 |
| Takahashi, M | 1 |
| Satomi, K | 1 |
| Sasaki, N | 1 |
| Kobayashi, T | 1 |
| Uchida, E | 1 |
| Kawauchi, D | 1 |
| Nakano, T | 1 |
| Fujii, T | 1 |
| Narita, Y | 1 |
| Kondo, A | 1 |
| Wada, K | 1 |
| Yoshino, A | 1 |
| Ichimura, K | 1 |
| Tomiyama, A | 1 |
| McBain, C | 1 |
| Lawrie, TA | 1 |
| Rogozińska, E | 1 |
| Kernohan, A | 1 |
| Robinson, T | 1 |
| Jefferies, S | 1 |
| Leal, CTS | 1 |
| Costa, LJM | 1 |
| Pereira, J | 1 |
| Duarte, FB | 1 |
| Tavares, RB | 1 |
| Atalla, A | 1 |
| Sabioni, BS | 1 |
| Neto, AEH | 1 |
| Beltzig, L | 1 |
| Christmann, M | 1 |
| Kaina, B | 1 |
| Aquilanti, E | 1 |
| Wen, PY | 3 |
| Le Rhun, E | 4 |
| Oppong, FB | 3 |
| van den Bent, M | 6 |
| Wick, W | 7 |
| Brandes, AA | 7 |
| Taphoorn, MJ | 7 |
| Platten, M | 4 |
| Idbaih, A | 4 |
| Clement, PM | 3 |
| Preusser, M | 3 |
| Golfinopoulos, V | 3 |
| Gorlia, T | 5 |
| Weller, M | 10 |
| Ellingson, BM | 1 |
| Chang, SM | 1 |
| Vogelbaum, MA | 1 |
| Li, G | 1 |
| Li, S | 1 |
| Kim, J | 1 |
| Youssef, G | 1 |
| Lassman, AB | 1 |
| Gilbert, MR | 3 |
| de Groot, JF | 1 |
| Galanis, E | 2 |
| Cloughesy, TF | 1 |
| Esparragosa Vazquez, I | 1 |
| Ndiaye, M | 1 |
| Di Stefano, AL | 1 |
| Younan, N | 1 |
| Larrieu-Ciron, D | 1 |
| Seyve, A | 1 |
| Picart, T | 1 |
| Meyronet, D | 1 |
| Boutet, C | 1 |
| Vassal, F | 1 |
| Carpentier, C | 1 |
| Figarella-Branger, D | 1 |
| Dehais, C | 1 |
| Forest, F | 1 |
| Rivoirard, R | 1 |
| Ducray, F | 2 |
| Look, T | 1 |
| Puca, E | 1 |
| Bühler, M | 1 |
| Kirschenbaum, D | 1 |
| De Luca, R | 1 |
| Stucchi, R | 1 |
| Ravazza, D | 1 |
| Di Nitto, C | 1 |
| Roth, P | 2 |
| Katzenelenbogen, Y | 1 |
| Weiner, A | 1 |
| Rindlisbacher, L | 1 |
| Becher, B | 1 |
| Amit, I | 1 |
| Neri, D | 1 |
| Hemmerle, T | 1 |
| Weiss, T | 2 |
| Mukherjee, S | 1 |
| Wood, J | 1 |
| Liaquat, I | 1 |
| Stapleton, SR | 1 |
| Martin, AJ | 1 |
| Indraccolo, S | 1 |
| De Salvo, GL | 1 |
| Verza, M | 1 |
| Caccese, M | 1 |
| Esposito, G | 1 |
| Piga, I | 1 |
| Del Bianco, P | 1 |
| Pizzi, M | 1 |
| Gardiman, MP | 1 |
| Eoli, M | 2 |
| Rudà, R | 2 |
| Ibrahim, T | 1 |
| Rizzato, S | 1 |
| Lolli, I | 1 |
| Zagonel, V | 1 |
| Lombardi, G | 1 |
| Kickingereder, P | 1 |
| Brugnara, G | 1 |
| Hansen, MB | 1 |
| Nowosielski, M | 1 |
| Pflüger, I | 1 |
| Schell, M | 1 |
| Isensee, F | 1 |
| Foltyn, M | 1 |
| Neuberger, U | 1 |
| Kessler, T | 1 |
| Sahm, F | 1 |
| Wick, A | 2 |
| Heiland, S | 1 |
| von Deimling, A | 2 |
| Maier-Hein, KH | 1 |
| Østergaard, L | 1 |
| van den Bent, MJ | 11 |
| Bendszus, M | 1 |
| Cai, Y | 1 |
| Jiang, YG | 1 |
| Wang, M | 1 |
| Jiang, ZH | 1 |
| Tan, ZG | 1 |
| Smallwood, K | 1 |
| Harper, A | 1 |
| Blackwood, L | 1 |
| Maddox, JM | 1 |
| Horan, M | 1 |
| Tafesh, L | 1 |
| Shrubsole, C | 1 |
| Osborne, W | 1 |
| Lin, P | 1 |
| Jiang, H | 1 |
| Zhao, YJ | 1 |
| Pang, JS | 1 |
| Liao, W | 1 |
| He, Y | 1 |
| Lin, ZY | 1 |
| Yang, H | 1 |
| Capper, D | 1 |
| Carpentier, AF | 2 |
| Kesari, S | 1 |
| Sepulveda-Sanchez, JM | 1 |
| Wheeler, HR | 1 |
| Chinot, O | 2 |
| Cher, L | 2 |
| Steinbach, JP | 2 |
| Specenier, P | 1 |
| Rodon, J | 1 |
| Cleverly, A | 1 |
| Smith, C | 1 |
| Gueorguieva, I | 1 |
| Miles, C | 1 |
| Guba, SC | 1 |
| Desaiah, D | 1 |
| Estrem, ST | 1 |
| Lahn, MM | 1 |
| Bavcar, S | 1 |
| de Vos, J | 1 |
| Kessler, M | 1 |
| de Fornel, P | 1 |
| Buracco, P | 1 |
| Murphy, S | 1 |
| Hirschberger, J | 1 |
| Argyle, DJ | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Duerinck, J | 3 |
| Du Four, S | 3 |
| Bouttens, F | 2 |
| Andre, C | 1 |
| Verschaeve, V | 2 |
| Van Fraeyenhove, F | 1 |
| Chaskis, C | 1 |
| D'Haene, N | 2 |
| Le Mercier, M | 2 |
| Rogiers, A | 1 |
| Michotte, A | 3 |
| Salmon, I | 2 |
| Neyns, B | 4 |
| Ameratunga, M | 1 |
| Pavlakis, N | 2 |
| Wheeler, H | 2 |
| Grant, R | 2 |
| Simes, J | 1 |
| Khasraw, M | 2 |
| Nakamura, S | 1 |
| Kawaguchi, K | 1 |
| Fukui, T | 1 |
| Hakiri, S | 1 |
| Ozeki, N | 1 |
| Mori, S | 1 |
| Goto, M | 1 |
| Hashimoto, K | 1 |
| Ito, T | 1 |
| Yokoi, K | 1 |
| Batchelor, TT | 1 |
| Mulholland, P | 1 |
| Nabors, LB | 1 |
| Campone, M | 1 |
| Mason, W | 2 |
| Mikkelsen, T | 1 |
| Phuphanich, S | 2 |
| Ashby, LS | 1 |
| Degroot, J | 1 |
| Gattamaneni, R | 1 |
| Rosenthal, M | 1 |
| Payer, F | 1 |
| Jürgensmeier, JM | 1 |
| Jain, RK | 1 |
| Sorensen, AG | 1 |
| Xu, J | 1 |
| Liu, Q | 1 |
| Thiepold, AL | 1 |
| Lemercier, S | 1 |
| Franz, K | 1 |
| Atta, J | 1 |
| Sulzbacher, A | 1 |
| Rieger, J | 1 |
| Taylor, RE | 1 |
| Howman, AJ | 1 |
| Wheatley, K | 1 |
| Brogden, EE | 1 |
| Large, B | 1 |
| Gibson, MJ | 1 |
| Robson, K | 1 |
| Mitra, D | 1 |
| Saran, F | 1 |
| Michalski, A | 2 |
| Pizer, BL | 1 |
| Tonder, M | 1 |
| Eisele, G | 1 |
| Hofer, S | 1 |
| Seystahl, K | 1 |
| Valavanis, A | 1 |
| Stupp, R | 3 |
| Rahman, R | 1 |
| Hempfling, K | 1 |
| Norden, AD | 1 |
| Reardon, DA | 1 |
| Nayak, L | 1 |
| Rinne, ML | 1 |
| Beroukhim, R | 1 |
| Doherty, L | 1 |
| Ruland, S | 1 |
| Rai, A | 1 |
| Rifenburg, J | 1 |
| LaFrankie, D | 1 |
| Alexander, BM | 1 |
| Huang, RY | 1 |
| Lee, EQ | 1 |
| Taal, W | 6 |
| Oosterkamp, HM | 3 |
| Walenkamp, AM | 3 |
| Dubbink, HJ | 1 |
| Beerepoot, LV | 4 |
| Hanse, MC | 3 |
| Buter, J | 3 |
| Honkoop, AH | 2 |
| Boerman, D | 1 |
| de Vos, FY | 3 |
| Dinjens, WN | 1 |
| Enting, RH | 1 |
| van den Berkmortel, FW | 1 |
| Jansen, RL | 1 |
| Brandsma, D | 1 |
| Bromberg, JE | 2 |
| van Heuvel, I | 1 |
| Vernhout, RM | 4 |
| van der Holt, B | 5 |
| Villanueva, MT | 2 |
| Ameratunga, MS | 1 |
| Raza, S | 1 |
| Firwana, B | 1 |
| Doll, DC | 1 |
| Gervais, R | 2 |
| Le Caer, H | 2 |
| Monnet, I | 1 |
| Falchero, L | 1 |
| Baize, N | 1 |
| Olivero, G | 1 |
| Thomas, P | 1 |
| Berard, H | 1 |
| Auliac, JB | 1 |
| Chouaid, C | 3 |
| Chamberlain, MC | 4 |
| Wong, ET | 1 |
| Lok, E | 1 |
| Swanson, KD | 1 |
| Dirven, L | 1 |
| Bottomley, A | 1 |
| van der Meer, N | 1 |
| Vos, MJ | 2 |
| Reijneveld, JC | 1 |
| Otten, A | 2 |
| Smits, M | 2 |
| Franceschi, E | 2 |
| Beije, N | 1 |
| Kraan, J | 1 |
| Beerepoot, L | 1 |
| Hanse, M | 2 |
| van Linde, ME | 1 |
| Gratama, JW | 1 |
| Sleijfer, S | 1 |
| Carvalho, BF | 1 |
| Fernandes, AC | 1 |
| Almeida, DS | 1 |
| Sampaio, LV | 1 |
| Costa, A | 1 |
| Caeiro, C | 1 |
| Osório, L | 1 |
| Castro, L | 1 |
| Linhares, P | 1 |
| Damasceno, M | 1 |
| Vaz, RC | 1 |
| Sander, W | 1 |
| Van Binst, AM | 2 |
| Everaert, H | 2 |
| Hau, P | 2 |
| Heiland, DH | 1 |
| Masalha, W | 1 |
| Franco, P | 1 |
| Machein, MR | 1 |
| Weyerbrock, A | 1 |
| Strowd, RE | 1 |
| Abuali, I | 1 |
| Ye, X | 1 |
| Lu, Y | 1 |
| Grossman, SA | 1 |
| Erdem-Eraslan, L | 1 |
| Hoogstrate, Y | 1 |
| Naz-Khan, H | 1 |
| Stubbs, A | 1 |
| van der Spek, P | 1 |
| Böttcher, R | 1 |
| Gao, Y | 1 |
| de Wit, M | 1 |
| Walenkamp, A | 1 |
| Sillevis Smitt, PA | 2 |
| Kros, JM | 3 |
| French, PJ | 1 |
| Vandervorst, F | 1 |
| Nakamoto, Y | 1 |
| Yamada, A | 1 |
| Uchida, K | 2 |
| Matsunaga, S | 1 |
| Ozawa, T | 1 |
| Wang, YF | 1 |
| Xu, WJ | 1 |
| Chen, YL | 1 |
| Ma, XH | 1 |
| Qiu, ZY | 1 |
| Ren, CA | 1 |
| Gahrmann, R | 1 |
| Vos, M | 1 |
| de Groot, JC | 1 |
| Flach, ZH | 1 |
| Jasperse, B | 1 |
| Baumert, BG | 1 |
| Lebeau, B | 3 |
| Baud, M | 1 |
| Masanès, MJ | 1 |
| Febvre, M | 1 |
| Puduvalli, VK | 2 |
| Cher, LM | 1 |
| Hong, S | 1 |
| Musib, L | 1 |
| Liepa, AM | 1 |
| Thornton, DE | 1 |
| Fine, HA | 1 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Hassan, A | 1 |
| Elias, DA | 1 |
| Fathallah-Shaykh, HM | 1 |
| Walbert, T | 1 |
| Groves, MD | 1 |
| Yung, WK | 2 |
| Conrad, CA | 1 |
| Bobustuc, GC | 1 |
| Colman, H | 1 |
| Hsu, SH | 1 |
| Bekele, BN | 1 |
| Qiao, W | 1 |
| Levin, VA | 6 |
| Sierra Del Rio, M | 1 |
| Ricard, D | 1 |
| Houillier, C | 1 |
| Navarro, S | 1 |
| Gonzalez-Aguilar, A | 1 |
| Kaloshi, G | 1 |
| Elhallani, S | 1 |
| Omuro, A | 1 |
| Choquet, S | 1 |
| Soussain, C | 1 |
| Hoang-Xuan, K | 1 |
| Vauleon, E | 1 |
| Mesbah, H | 1 |
| Gedouin, D | 1 |
| Lecouillard, I | 1 |
| Louvel, G | 1 |
| Hamlat, A | 1 |
| Riffaud, L | 1 |
| Carsin, B | 1 |
| Quillien, V | 1 |
| Audrain, O | 1 |
| Lesimple, T | 1 |
| Hasegawa, D | 1 |
| Kuwabara, T | 1 |
| Mizoguchi, S | 1 |
| Yayoshi, N | 1 |
| Fujita, M | 1 |
| van Herpen, C | 1 |
| Laigle Donadey, F | 1 |
| Hegi, M | 1 |
| Lhermitte, B | 1 |
| Strauss, LC | 1 |
| Allgeier, A | 1 |
| Lacombe, D | 1 |
| Packer, RJ | 3 |
| Zhou, T | 1 |
| Holmes, E | 1 |
| Vezina, G | 1 |
| Gajjar, A | 1 |
| Friedrich, C | 1 |
| von Bueren, AO | 1 |
| von Hoff, K | 1 |
| Kwiecien, R | 1 |
| Pietsch, T | 2 |
| Warmuth-Metz, M | 1 |
| Deinlein, F | 1 |
| Kuehl, J | 1 |
| Kortmann, RD | 2 |
| Rutkowski, S | 1 |
| Pizer, B | 1 |
| Salehzadeh, A | 1 |
| Brodbelt, A | 1 |
| Mallucci, C | 1 |
| Zander, T | 1 |
| Nettekoven, W | 1 |
| Kraus, JA | 1 |
| Pels, H | 1 |
| Ko, YD | 1 |
| Vetter, H | 1 |
| Klockgether, T | 1 |
| Schlegel, U | 1 |
| Baker, MJ | 1 |
| Brem, S | 1 |
| Daniels, S | 1 |
| Sherman, B | 1 |
| Macedoni-Luksic, M | 1 |
| Jereb, B | 2 |
| Todorovski, L | 1 |
| Looijenga, LH | 1 |
| Langenberg, K | 1 |
| Dinjens, W | 1 |
| Graveland, W | 1 |
| Uytdewilligen, L | 1 |
| Jenkins, RB | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Heimans, JJ | 3 |
| Baayen, HC | 1 |
| Boogerd, W | 2 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Postma, TJ | 3 |
| Bravo Marques, J | 1 |
| van der Rijt, CC | 1 |
| Vecht, CJ | 1 |
| De Beule, N | 1 |
| Baron, B | 1 |
| Sunyach, MP | 1 |
| Pommier, P | 1 |
| Martel Lafay, I | 1 |
| Guyotat, J | 1 |
| Ginestet, G | 1 |
| Jouanneau, E | 1 |
| Jouvet, A | 3 |
| Sindou, M | 3 |
| Bret, P | 2 |
| Carrie, C | 1 |
| Frappaz, D | 1 |
| Bertolone, SJ | 1 |
| Yates, AJ | 1 |
| Boyett, JM | 1 |
| Wallace, D | 1 |
| Finlay, JL | 1 |
| Lancaster, DL | 1 |
| Hoddes, JA | 1 |
| Lichy, MP | 1 |
| Bachert, P | 1 |
| Henze, M | 1 |
| Lichy, CM | 1 |
| Debus, J | 1 |
| Schlemmer, HP | 1 |
| Soffietti, R | 1 |
| Nobile, M | 1 |
| Borgognone, M | 1 |
| Costanza, A | 1 |
| Laguzzi, E | 1 |
| Mutani, R | 1 |
| Shamash, J | 1 |
| Dancey, G | 1 |
| Barlow, C | 1 |
| Wilson, P | 1 |
| Ansell, W | 1 |
| Oliver, RT | 1 |
| Musolino, A | 1 |
| Perrone, MA | 1 |
| Michiara, M | 1 |
| Delnevo, D | 1 |
| Franciosi, V | 1 |
| Di Blasio, B | 1 |
| Ceci, G | 1 |
| Camisa, R | 1 |
| Ardizzoni, A | 1 |
| Cocconi, G | 2 |
| Spreafico, F | 1 |
| Massimino, M | 1 |
| Gandola, L | 1 |
| Cefalo, G | 1 |
| Mazza, E | 1 |
| Landonio, G | 1 |
| Pignoli, E | 1 |
| Poggi, G | 1 |
| Terenziani, M | 1 |
| Pedrazzoli, P | 1 |
| Siena, S | 1 |
| Fossati-Bellani, F | 1 |
| Berry, WR | 1 |
| Stiefel, M | 1 |
| Reiss, T | 1 |
| Staege, MS | 1 |
| Rengelshausen, J | 1 |
| Burhenne, J | 1 |
| Wawer, A | 1 |
| Foell, JL | 1 |
| Rutkauskiene, G | 1 |
| Labanauskas, L | 1 |
| Mabasa, VH | 1 |
| Taylor, SC | 1 |
| Walker, C | 1 |
| Haylock, B | 1 |
| Husband, D | 1 |
| Joyce, KA | 1 |
| Fildes, D | 1 |
| Jenkinson, MD | 1 |
| Smith, T | 1 |
| Broome, J | 1 |
| Kopitzki, K | 1 |
| du Plessis, DG | 1 |
| Prosser, J | 1 |
| Vinjamuri, S | 1 |
| Warnke, PC | 1 |
| Rusk, A | 1 |
| Cozzi, E | 1 |
| Stebbins, M | 1 |
| Vail, D | 1 |
| Graham, J | 1 |
| Valli, V | 1 |
| Henkin, J | 1 |
| Sharpee, R | 1 |
| Khanna, C | 1 |
| Cheng, S | 1 |
| Evans, WK | 1 |
| Stys-Norman, D | 1 |
| Shepherd, FA | 1 |
| Le Guen, Y | 1 |
| Paillotin, D | 1 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Rassnick, KM | 1 |
| Williams, LE | 1 |
| Kristal, O | 1 |
| Al-Sarraf, R | 1 |
| Baez, JL | 1 |
| Zwahlen, CH | 1 |
| Dank, G | 1 |
| Huang, AT | 1 |
| Lucas, VS | 1 |
| Baughn, SG | 1 |
| Cole, TB | 1 |
| Harker, WG | 1 |
| Kushlan, P | 1 |
| Rosenberg, SA | 1 |
| Jellinger, K | 1 |
| Volc, D | 1 |
| Grisold, W | 1 |
| Podreka, I | 1 |
| Böck, F | 1 |
| Schuster, H | 1 |
| Alth, G | 1 |
| Kogelnik, HD | 1 |
| Smyth, JF | 1 |
| Ford, HT | 1 |
| Poplin, EA | 1 |
| Aisner, J | 1 |
| Van Echo, DA | 1 |
| Whitacre, M | 1 |
| Wiernik, PH | 1 |
| Karrer, K | 1 |
| Denck, H | 1 |
| Pridun, N | 1 |
| Zwintz, E | 1 |
| Niederle, N | 1 |
| Krischke, W | 1 |
| Bremer, K | 1 |
| Schmidt, CG | 1 |
| Seeber, S | 1 |
| Briancon, S | 1 |
| Thisse, JY | 1 |
| Watrin, H | 1 |
| Feintrenie, X | 1 |
| Lamaze, R | 1 |
| Lamy, P | 1 |
| Hill, GJ | 1 |
| Krementz, ET | 1 |
| Hill, HZ | 1 |
| Ojala, A | 1 |
| Nikkanen, VN | 1 |
| Paloheimo, S | 1 |
| Palojoki, A | 1 |
| Thölix, E | 1 |
| Baĭsogolov, GD | 2 |
| Shakhtarina, SV | 2 |
| Heinz, R | 1 |
| Hanak, H | 1 |
| Shields, TW | 1 |
| Higgins, GA | 1 |
| Humphrey, EW | 1 |
| Matthews, MJ | 1 |
| Keehn, RJ | 1 |
| Gropp, C | 1 |
| Havemann, K | 1 |
| Vialushkin, BIa | 1 |
| Koshel', IV | 1 |
| Tsyplenkov, VG | 1 |
| Wilson, CB | 4 |
| Vestnys, PS | 1 |
| Casotto, A | 1 |
| Buoncristiani, P | 1 |
| Reid, A | 1 |
| Ahuja, RK | 1 |
| Fuchs, R | 2 |
| Löffler, M | 2 |
| Pfreundschuh, M | 2 |
| Dölken, G | 2 |
| Gerhartz, H | 2 |
| Hagen-Aukamp, U | 2 |
| Hiller, E | 2 |
| Petsch, S | 2 |
| Pflüger, KH | 2 |
| Rühl, U | 2 |
| Sobol, RE | 1 |
| Fakhrai, H | 1 |
| Shawler, D | 1 |
| Gjerset, R | 1 |
| Dorigo, O | 1 |
| Carson, C | 1 |
| Khaleghi, T | 1 |
| Koziol, J | 1 |
| Shiftan, TA | 1 |
| Royston, I | 1 |
| Cole, SJ | 1 |
| Fraser, DE | 1 |
| Whittle, IR | 1 |
| Cairncross, JG | 3 |
| Le Chevalier, T | 3 |
| Arriagada, R | 3 |
| Quoix, E | 1 |
| Ruffie, P | 2 |
| Martin, M | 1 |
| Douillard, JY | 1 |
| Tarayre, M | 1 |
| Lacombe-Terrier, MJ | 1 |
| Laplanche, A | 1 |
| Dorigo, A | 1 |
| Mansberg, R | 1 |
| Kwan, YL | 1 |
| Bjerrum, OW | 1 |
| Kiss, K | 1 |
| Daugaard, G | 1 |
| Dautzenberg, B | 1 |
| Chastang, C | 2 |
| Belpomme, D | 1 |
| Hurdebourcq, M | 1 |
| Fabre, C | 1 |
| Charvolin, P | 1 |
| Guérin, RA | 1 |
| Kyritsis, AP | 1 |
| Jaeckle, KA | 1 |
| Bruner, J | 1 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Hayat, K | 1 |
| Jones, B | 1 |
| Bisbrown, G | 1 |
| Baria, K | 1 |
| Pigott, T | 1 |
| Kormanik, PA | 1 |
| Bouffet, E | 2 |
| Mornex, F | 1 |
| Thiesse, P | 2 |
| Mertens, P | 1 |
| Helfre, S | 1 |
| van Groeningen, CJ | 2 |
| Witjes, RJ | 1 |
| Weerts, JG | 1 |
| Kralendonk, JH | 1 |
| Arcicasa, M | 1 |
| Roncadin, M | 1 |
| Bidoli, E | 1 |
| Dedkov, A | 1 |
| Gigante, M | 1 |
| Trovò, MG | 1 |
| Lippens, RJ | 1 |
| Rotteveel, JJ | 1 |
| Otten, BJ | 1 |
| Merx, H | 1 |
| Herrlinger, U | 1 |
| Brugger, W | 1 |
| Bamberg, M | 2 |
| Küker, W | 1 |
| Dichgans, J | 1 |
| Boiardi, A | 2 |
| Pozzi, A | 1 |
| Salmaggi, A | 1 |
| Broggi, G | 2 |
| Silvani, A | 2 |
| Deininger, MH | 1 |
| Grote, E | 1 |
| Wickboldt, J | 1 |
| Meyermann, R | 1 |
| Kappelle, AC | 1 |
| Groeneveld, GJ | 1 |
| Zonnenberg, BA | 1 |
| Sneeuw, KC | 1 |
| Eich, HT | 1 |
| Staar, S | 1 |
| Micke, O | 1 |
| Eich, PD | 1 |
| Stützer, H | 1 |
| Müller, R | 1 |
| Valencak, J | 1 |
| Dietrich, W | 1 |
| Raderer, M | 1 |
| Dieckmann, K | 2 |
| Prayer, D | 1 |
| Hainfellner, JA | 1 |
| Marosi, C | 1 |
| Cairncross, G | 1 |
| Swinnen, L | 1 |
| Bayer, R | 1 |
| Rosenfeld, S | 1 |
| Salzman, D | 1 |
| Paleologos, N | 1 |
| Kaminer, L | 1 |
| Forsyth, P | 1 |
| Stewart, D | 1 |
| Peterson, K | 1 |
| Hu, W | 1 |
| Macdonald, D | 1 |
| Ramsay, D | 1 |
| Smith, A | 1 |
| Greenberg, HS | 1 |
| Glantz, MJ | 1 |
| Wang, S | 1 |
| Wagenaar, HC | 1 |
| Colombo, N | 1 |
| Vergote, I | 1 |
| Hoctin-Boes, G | 1 |
| Zanetta, G | 1 |
| Pecorelli, S | 1 |
| Lacave, AJ | 1 |
| van Hoesel, Q | 1 |
| Cervantes, A | 1 |
| Bolis, G | 1 |
| Namer, M | 1 |
| Lhommé, C | 1 |
| Guastalla, JP | 1 |
| Nooij, MA | 1 |
| Poveda, A | 1 |
| Scotto di Palumbo, V | 1 |
| Vermorken, JB | 1 |
| Timmermann, B | 1 |
| Kühl, J | 1 |
| Meisner, C | 1 |
| Reagan, TJ | 1 |
| Bisel, HF | 1 |
| Childs, DS | 1 |
| Layton, DD | 1 |
| Rhoton, AL | 1 |
| Taylor, WF | 1 |
| Ertel, IJ | 3 |
| Boesel, C | 2 |
| Heiss, WD | 2 |
| Turnheim, M | 1 |
| Mamoli, B | 1 |
| Lehnert, M | 1 |
| Hartmann, D | 1 |
| Obrecht, JP | 1 |
| Stalder, GA | 1 |
| Seiler, RW | 1 |
| Vassella, F | 1 |
| Markwalder, H | 1 |
| Poisson, M | 2 |
| Pouillart, P | 2 |
| Bataini, JP | 2 |
| Mashaly, R | 2 |
| Pertuiset, BF | 2 |
| Metzger, J | 2 |
| Hauw, JJ | 1 |
| Crafts, DC | 1 |
| Edwards, MS | 2 |
| Pischer, TL | 1 |
| Salmon, SE | 1 |
| Carter, SK | 1 |
| Milanesi, I | 1 |
| Fariselli, L | 1 |
| Allard, P | 1 |
| Migueres, J | 1 |
| Boita, F | 1 |
| Fichet, D | 1 |
| Pyrich, M | 1 |
| Gościński, I | 1 |
| Krzyszkowski, T | 1 |
| Glimelius, B | 1 |
| Påhlman, L | 1 |
| Macdonald, DR | 2 |
| Ramsay, DA | 1 |
| Afanasova, NV | 1 |
| Lefkowitz, IB | 2 |
| Siegel, KR | 2 |
| Sutton, LN | 2 |
| Schut, L | 2 |
| Evans, AE | 4 |
| Hafström, L | 1 |
| Domellöf, L | 1 |
| Rudenstam, CM | 1 |
| Norryd, C | 1 |
| Bergman, L | 1 |
| Nilsson, T | 1 |
| Hansson, K | 1 |
| Wählby, L | 1 |
| Asklöf, G | 1 |
| Kugelberg, C | 1 |
| Jenkin, RD | 3 |
| Sposto, R | 3 |
| Ortega, JA | 2 |
| Wara, W | 3 |
| Kramer, S | 1 |
| Chang, CH | 1 |
| Leikin, SL | 1 |
| Nõu, E | 1 |
| Brodin, O | 1 |
| Bergh, J | 1 |
| Bleehen, NM | 1 |
| Freedman, LS | 1 |
| Stenning, SP | 1 |
| Boesel, CP | 1 |
| Venes, JL | 1 |
| Hammond, D | 1 |
| Curley, SA | 1 |
| Roh, MS | 1 |
| Rich, TA | 1 |
| Marangolo, M | 1 |
| Pezzuoli, G | 1 |
| Marubini, E | 1 |
| Amadori, D | 1 |
| Boracchi, P | 1 |
| Cunsolo, A | 1 |
| Garcea, D | 1 |
| Germiniani, R | 1 |
| Luporini, G | 1 |
| Domingo Albós, A | 1 |
| Callís, M | 1 |
| Juliá, A | 1 |
| Vilá, J | 1 |
| Zuazu, J | 1 |
| Puig, J | 1 |
| Petit, J | 1 |
| Fernández-Sevilla, A | 1 |
| Friedman, HS | 1 |
| Schold, SC | 1 |
| Djang, WT | 1 |
| Kurtzberg, J | 1 |
| Longee, DC | 1 |
| Halperin, EC | 1 |
| Falletta, JM | 1 |
| Coleman, RE | 1 |
| Oakes, WJ | 1 |
| Thomas, F | 1 |
| Baldeyrou, P | 1 |
| Fulton, DS | 1 |
| Urtasun, RC | 1 |
| McKinnon, S | 1 |
| Tanasichuk, H | 1 |
| Pendergrass, TW | 1 |
| Milstein, JM | 1 |
| Geyer, JR | 1 |
| Mulne, AF | 1 |
| Kosnik, EJ | 1 |
| Morris, JD | 1 |
| Heideman, RL | 1 |
| Ruymann, FB | 1 |
| Stuntz, JT | 1 |
| Bleyer, WA | 1 |
| Eagan, RT | 1 |
| Frytak, S | 1 |
| Richardson, RL | 1 |
| Creagan, ET | 1 |
| Nichols, WC | 1 |
| Hughes, EN | 1 |
| Shillito, J | 1 |
| Sallan, SE | 1 |
| Loeffler, JS | 1 |
| Cassady, JR | 1 |
| Tarbell, NJ | 1 |
| Bruce, DA | 1 |
| Rodriguez, LA | 1 |
| Prados, M | 1 |
| Fulton, D | 1 |
| Silver, P | 1 |
| Levin, V | 1 |
| de Graeff, A | 1 |
| de Groot, JA | 1 |
| Schornagel, JH | 1 |
| Ertel, I | 1 |
| Evans, A | 1 |
| Hittle, R | 1 |
| Ortega, J | 1 |
| Wilson, C | 1 |
| Anderson, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone[NCT00777153] | Phase 3 | 423 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Precoce Medical Care by the Mobil Support for Patients With Glioblastoma Receiving Specific Medical Oncology Treatment[NCT04516733] | 35 participants (Actual) | Interventional | 2019-05-10 | Completed | |||
| Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma[NCT02698280] | Phase 2 | 23 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma[NCT00295815] | Phase 3 | 397 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304] | Phase 2 | 29 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas[NCT01445119] | Phase 1 | 58 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.) | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of patients alive and progression free at 6 months (based on central review) as estimated from Kaplan-Meier techniques. Values are percentages. (NCT00777153)
Timeframe: 6 Months
| Intervention | % of patients alive and progression free (Number) |
|---|---|
| Cediranib 30mg | 16.2 |
| Cediranib 20mg + Lomustine 100mg | 34.5 |
| Lomustine 100mg | 24.5 |
The mean steroid dosage prior to treatment will be considered as the patient's baseline. The percent change in average daily steroid dosage from baseline is calculated by following formula: PC = (md - bm)/bm*100; where PC is the percent change in average daily steroid dosage from baseline; md the mean daily steroid dosage recorded from the first day of therapy to progression; and bm the baseline mean. (NCT00777153)
Timeframe: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assed up to 2014-April-25
| Intervention | percentage of change (Number) |
|---|---|
| Cediranib 30mg | -17.6 |
| Cediranib 20mg + Lomustine 110mg | -1.8 |
| Lomustine 110mg | 36.6 |
Number of months from randomisation to the date of death from any cause (NCT00777153)
Timeframe: Baseline through to date of death up to 25th April 2010
| Intervention | Months (Median) |
|---|---|
| Cediranib 30mg | 8.0 |
| Cediranib 20mg + Lomustine 110mg | 9.4 |
| Lomustine 110mg | 9.8 |
"For patients with measurable disease at entry (at least one lesion that has a shortest diameter~≥10 mm at baseline on 2 axial slices), PFS will be defined as the earliest time that:~The sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions has increased by a greater than or equal to 25% in comparison to the nadir scan as long as the shortest diameter is ≥15 mm. If the dose of steroids has been reduced within the 10 days prior to the scan being conducted, progression will be based on a follow-up scan performed after the dose of steroids has been stabilized for 10 days.~The patient has died from any cause.~A new lesion is detected that is outside the original tumor volume and has a shortest diameter ≥10 mm." (NCT00777153)
Timeframe: Baseline at 6 weeks and then every 6 weeks to discontinuation
| Intervention | Days (Median) |
|---|---|
| Cediranib 30mg | 92 |
| Cediranib 20mg+ Lomustine 110mg | 125 |
| Lomustine 110mg | 82 |
"An individual visit response of PR was defined as a greater than or equal to 50% reduction in the sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions compared to baseline as long as the steroid dose has not been increased within the previous 10 days and no new lesions are present.~An individual visit response of CR was defined as the complete disappearance of all tumor on MRI scan." (NCT00777153)
Timeframe: Baseline at 6 weeks and then every 6 weeks to discontinuation
| Intervention | Participants (Number) |
|---|---|
| Cediranib 30mg | 18 |
| Cediranib 20mg + Lomustine 110mg | 21 |
| Lomustine 110mg | 5 |
Number of days known not to have used any steroids prior to progression (NCT00777153)
Timeframe: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assessed up to 2014-April-25
| Intervention | Days (Mean) |
|---|---|
| Cediranib 30mg | 75.8 |
| Cediranib 20mg + Lomustine 119mg | 74.8 |
| Lomustine 110mg | 92.3 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
16 reviews available for lomustine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
Topics: Brain Neoplasms; Glioblastoma; Humans; Lomustine; Neoplasm Recurrence, Local; Network Meta-Analysis | 2021 |
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2023 |
How did lomustine become standard of care in recurrent glioblastoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2020 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2018 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2014 |
Chemotherapy for diffuse low-grade gliomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother | 2011 |
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries | 2003 |
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small | 2007 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Ad | 1994 |
Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma.
Topics: Adult; Antineoplastic Agents, Alkylating; Choroid Plexus Neoplasms; Combined Modality Therapy; Femal | 2000 |
Adult medulloblastoma: multiagent chemotherapy.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebrospinal Flu | 2001 |
The value of adjuvant therapy after radical surgery for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 1992 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Crani | 1992 |
Surgical therapy of early rectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Fluorourac | 1989 |
Chemotherapy of primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl | 1985 |
54 trials available for lomustine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G | 2023 |
Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
Topics: Acetyl-CoA Carboxylase; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Female; G | 2020 |
Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Contrast M | 2020 |
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4-CD8 Ratio; Cytokines; | 2017 |
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating | 2018 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas | 2013 |
Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemoradiotherapy; | 2014 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl | 2014 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl | 2014 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl | 2014 |
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl | 2014 |
Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protoc | 2015 |
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2015 |
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Combined Chemotherapy P | 2015 |
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2015 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2016 |
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Axitinib; Bevacizumab; Brai | 2016 |
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Contrast Media; Gliobl | 2017 |
Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Glioblastoma; Humans; Indoles; Lomustine; Male; Middle Aged; N | 2010 |
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Disease-Fre | 2012 |
Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemoradiot | 2013 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Combined modality therapy for poorly differentiated gliomas of the posterior fossa in children: a Children's Cancer Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Cell Differentiation; Cereb | 2003 |
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi | 2003 |
Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2004 |
Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; | 2005 |
Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Progressio | 2006 |
[Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501)].
Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineop | 2007 |
A trial of outpatient chemotherapy for recurrent head and neck tumors.
Topics: Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Adm | 1980 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1984 |
Combination chemotherapy in metastatic or recurrent non-small cell bronchogenic carcinoma. 5-year results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Clinical Trial | 1983 |
Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung.
Topics: Carcinoma; Clinical Trials as Topic; Humans; Hydroxyurea; Lomustine; Lung Neoplasms; Male; Neoplasm | 1982 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1994 |
Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lun | 1994 |
Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 1995 |
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 1997 |
PCV salvage chemotherapy for recurrent primary CNS lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Huma | 2000 |
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2001 |
Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Comb | 2002 |
Controlled study of CCNU and radiation therapy in malignant astrocytoma.
Topics: Adult; Aged; Brain Neoplasms; Digestive System; Drug Evaluation; Glioblastoma; Hematopoiesis; Humans | 1976 |
Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma--final evaluation. E.O.R.T.C. Brain Tumor Group.
Topics: Brain Neoplasms; Clinical Trials as Topic; Female; Glioma; Humans; Lomustine; Male; Neoplasm Recurre | 1978 |
Nitrosoureas in multiple myeloma.
Topics: Carmustine; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Human | 1976 |
Effect of CCNU on survival, rate of objective remission and duration of free interval in patients with malignant brain glioma--first evaluation.
Topics: Brain Neoplasms; Dexamethasone; Glioma; Humans; Lomustine; Neoplasm Recurrence, Local; Nitrosourea C | 1976 |
[Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1992 |
Efficacy of '8-drugs-in-one-day' combination in treatment of recurrent GBM patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Glioblastoma; Huma | 1992 |
Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxor | 1992 |
The value of adjuvant therapy after radical surgery for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 1992 |
Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1990 |
The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Child, Pres | 1990 |
A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, | 1988 |
A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party.
Topics: Adolescent; Adult; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Double-Blin | 1989 |
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 1989 |
Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Results of a multicentric randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1989 |
Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1987 |
106 other studies available for lomustine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2021 |
Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell | 2022 |
Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.
Topics: Artesunate; Cellular Senescence; Curcumin; Glioblastoma; Humans; Lomustine; Neoplasm Recurrence, Loc | 2022 |
Current therapeutic options for glioblastoma and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Glioblas | 2022 |
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Magnetic Resonan | 2023 |
Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma.
Topics: Animals; Disease Models, Animal; Glioblastoma; Lomustine; Mice; Neoplasm Recurrence, Local; T-Lympho | 2023 |
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; | 2020 |
Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Cyclophosphamide; Cytar | 2021 |
DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2021 |
Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2021 |
Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dog Dise | 2017 |
Multimodality therapy for thymoma patients with pleural dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; | 2019 |
Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Disease-Free Sur | 2014 |
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Renewing interest in targeting angiogenesis in glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Lomus | 2014 |
CNS cancer: it takes two to tango.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Lomus | 2014 |
Neuro-oncology: It takes two to tango.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N | 2014 |
Bevacizumab alone or in combination with chemotherapy in glioblastomas?
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N | 2014 |
Bevacizumab alone or in combination with chemotherapy in glioblastomas?--authors' reply.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N | 2014 |
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi | 2015 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2015 |
The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N | 2015 |
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe | 2015 |
Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Female; Follow- | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
Case of a miniature dachshund with a primitive neuroectodermal tumor confined to the forebrain region treated with a combination of surgery and chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dog Diseases | 2016 |
[Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin | 2016 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Prophylactic intrathecal chemotherapy in primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Long-term survival in a dog with anaplastic oligodendroglioma treated with radiation therapy and CCNU.
Topics: Animals; Dog Diseases; Dogs; Fatal Outcome; Immunohistochemistry; Lomustine; Magnetic Resonance Imag | 2012 |
Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherapy, Adj | 2013 |
Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent grade III astrocytoma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combi | 2013 |
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female | 2002 |
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Femal | 2002 |
Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Brain Damage, Chronic; B | 2003 |
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes | 2003 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Astrocytoma; Brain Neoplasms; | 2004 |
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A | 2005 |
Survival of adults treated for medulloblastoma using paediatric protocols.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar | 2005 |
Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; Drug Resista | 2005 |
Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma.
Topics: Administration, Oral; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus | 2007 |
Treatment of patients of high-risk group of medulloblastoma with the adjuvant lomustine, cisplatin, and vincristine chemotherapy.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytoge | 2005 |
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia | 2006 |
Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, | 2006 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).
Topics: Animals; Antineoplastic Agents, Alkylating; Cat Diseases; Cats; Female; Kaplan-Meier Estimate; Lomus | 2008 |
Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 1984 |
Multimodality treatment of malignant gliomas. Comparison of several adjuvant approaches.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Drug Therapy, Combination; Ependymoma; Glioblastoma; | 1981 |
Methotrexate in the chemotherapy of lung cancer.
Topics: Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos | 1981 |
CCNU, vincristine, methotrexate, and procarbazine treatment of relapsed small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Drug Therapy | 1982 |
[Prevention of recurrence of small-cell lung cancer by adjuvant polychemotherapy (author's transl)].
Topics: Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Human | 1982 |
Small-cell bronchogenic carcinoma--primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Drug Therapy, Co | 1982 |
[Triple biphasic chemotherapy in the treatment of small-cell bronchial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Small Cell; Combined | 1983 |
[3-year results of the combined treatment of stage I and II lymphogranulomatosis patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1984 |
Non-Hodgkin lymphoma following Hodgkin's disease. A case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Hodgkin Dis | 1984 |
[Chemotherapy of stomach cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cisplatin; Doxorubicin; Drug Administration Sched | 1982 |
[Treatment procedure in generalized lymphogranulomatosis in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1982 |
Medulloblastoma in childhood. Multidisciplinary treatment.
Topics: Adolescent; Carmustine; Cerebellar Neoplasms; Cerebellum; Child; Child, Preschool; Female; Humans; I | 1982 |
Patterns of failure in patients with medulloblastoma.
Topics: Adolescent; Adult; Aged; Cerebellar Neoplasms; Child; Child, Preschool; Cyclophosphamide; Dose-Respo | 1982 |
Interleukin-2 gene therapy in a patient with glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Combined Modality | 1995 |
Rapid resolution following chemotherapy of Broca's dysphasia due to recurrent anaplastic astrocytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aphasia, Broca; Astrocytoma; Fatal Outcome; Follow-U | 1994 |
Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lomustine; L | 1993 |
Combination chemotherapy with a five-drug regimen for invasive thymoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormon | 1996 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Retreatment of patients with intracranial gliomas by external beam radiotherapy and cytotoxic chemotherapy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Child; Combined Modality Therap | 1997 |
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gl | 1997 |
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1998 |
Reirradiation and lomustine in patients with relapsed high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease | 1999 |
Chemotherapy with Adriamycin (doxorubicin) and CCNU (lomustine) in four children with recurrent craniopharyngioma.
Topics: Adolescent; Antineoplastic Agents; Child, Preschool; Combined Modality Therapy; Craniopharyngioma; D | 1998 |
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy | 1999 |
Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1998 |
Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apop | 2000 |
PCV chemotherapy for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Glioblasto | 2001 |
Radiotherapy of esthesioneuroblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Da | 2001 |
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 2000 |
Brain tumors in children.
Topics: Adolescent; Astrocytoma; Brain; Brain Neoplasms; Child; Diagnosis, Differential; Ependymoma; Female; | 1978 |
Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Meth | 1978 |
[Status and problems of the treatment of metastatic rectal cancer].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Neoplasm Recurren | 1979 |
[Clinical and therapeutic study (phase II) using VP-16/213 and methyl-CCNU in patients with inoperable, recurring or metastasizing carcinomas of the gastriointestinal tract].
Topics: Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Hum | 1978 |
Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Drug Therapy, Combination; Female; Humans; Lomustin | 1979 |
Malignant gliomas treated after surgery by combination chemotherapy and delayed irradiation. Part I: Analysis of results.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Cobalt Radioisotopes; Drug Therapy, Combinati | 1979 |
Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy.
Topics: Brain; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Neoplasm Recurrence, L | 1979 |
Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combination; Humans; Lomu | 1978 |
Chemotherapy of malignant gliomas: comparison of the effect of polychemo- and CCNU-therapy.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Therapy, Combination; Humans; | 1978 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
[Diagnosis and treatment of recurrent brain glioma].
Topics: Adult; Brain Neoplasms; Cobalt Radioisotopes; Female; Glioma; Humans; Lomustine; Male; Middle Aged; | 1992 |
[The combined (polychemical and radiation) and drug treatment of lymphogranulomatosis patients with generalized lung involvement (stage IV)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Hodgkin | 1991 |
Chemotherapy for oligodendroglioma. Progress report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Recurre | 1991 |
Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Child; Child, Pres | 1990 |
[Vindesine, CCNU, high-dosage ara-C, and prednisolone (VINAP regimen) in the treatment of relapsing or refractory non-Hodgkin's lymphomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Drug | 1989 |
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Cohort S | 1989 |
Should chemotherapy response be evaluated separately in sequential chemotherapy-radiotherapy schedules in locally advanced nonsmall-cell lung carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1988 |
Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Diseases; Brain Neop | 1987 |
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Comb | 1987 |
Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Lomust | 1986 |
Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; | 1988 |
Results of the treatment of children with recurrent gliomas with lomustine and vincristine.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1988 |
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1988 |
Chemotherapy with doxorubicin and CCNU in advanced undifferentiated carcinoma of the nasopharynx. A retrospective report on five patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Female; H | 1987 |